International Clinical Trial: A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors

Geneva, April 28 -- International Clinical Trials Registry received information related to the study (NCT07537881) titled 'A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors' on April 12.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: RemeGen Co., Ltd.

Condition: Solid Tumors

Intervention: Drug: RC288 For Injection

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: April 30, 2026

Target Sample Size: 326

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07537881

D...